| Oct 23 |
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
|
| Oct 17 |
Adial Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Expanded Genotype Combinations Identified Using the Company’s Genetic Diagnostic for Addiction Treatment
|
| Oct 17 |
EXCLUSIVE: Adial Pharmaceuticals Secures Additional US Patent Expanding Intellectual Property Protection Around Its Alcohol Use Disorder Candidate
|
| Oct 15 |
Adial Pharmaceuticals Commends the National Institute on Alcohol Abuse and Alcoholism's New Definition of Recovery
|
| Sep 19 |
Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
|
| Sep 4 |
Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 15 |
Adial Pharmaceuticals reports Q2 results
|
| Aug 14 |
Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Aug 13 |
Adial Pharmaceuticals Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04
|
| Aug 13 |
EXCLUSIVE: Adial Pharmaceuticals Advances Regulatory Strategy For Companion Diagnostic Genetic Test For Its Lead Program For Alcohol Use Disorder
|
